"Pyrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterocyclic aromatic organic compounds with the chemical formula C4H4N2.
Descriptor ID |
D011719
|
MeSH Number(s) |
D03.383.679
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazines".
Below are MeSH descriptors whose meaning is more specific than "Pyrazines".
This graph shows the total number of publications written about "Pyrazines" by people in this website by year, and whether "Pyrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2002 | 1 | 0 | 1 |
2004 | 1 | 1 | 2 |
2010 | 1 | 0 | 1 |
2011 | 2 | 0 | 2 |
2012 | 1 | 1 | 2 |
2013 | 2 | 0 | 2 |
2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice. Endocrinology. 2014 Mar; 155(3):865-72.
-
Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways. J Pharm Pharmacol. 2014 Jan; 66(1):62-72.
-
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury. Exp Mol Pathol. 2013 Apr; 94(2):352-9.
-
The use of a reversible proteasome inhibitor in a model of Reduced-Size Orthotopic Liver transplantation in rats. Exp Mol Pathol. 2012 Aug; 93(1):99-110.
-
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Exp Mol Pathol. 2012 Aug; 93(1):26-34.
-
Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
-
Proteasome inhibitor treatment in alcoholic liver disease. World J Gastroenterol. 2011 May 28; 17(20):2558-62.
-
Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease. Exp Mol Pathol. 2011 Feb; 90(1):123-30.
-
Proteasome inhibition induces cytokeratin accumulation in vivo. Exp Mol Pathol. 2004 Apr; 76(2):83-9.
-
The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation. Exp Mol Pathol. 2004 Feb; 76(1):9-16.